COVID-19 message from World Hepatitis Alliance president, Su Wang

Dear Colleagues,

As the COVID-19 (Coronavirus) pandemic spreads across the globe, it is affecting all of our lives.

WHA members have always worked passionately with some of the most marginalised and underserved communities in the world and these communities will also be disproportionately affected by COVID-19.

I know every one of our members will be working around the clock to minimize the impact of this pandemic on their communities and fight for the rights of their patients.

Many people affected by viral hepatitis are concerned about potential additional risks they may face if they contract COVID-19. While the advice for hepatitis patients is being developed, we will monitor the situation and share all relevant information with you as soon as possible.

I understand how challenging this time will be for your organisations. The stark reality is that many WHA members face suspending vital prevention, testing and treatment services. We recognise that restrictions may have financial implications which will put a strain on organisations.

WHA stands with you and is working hard to adapt so we can support you, patients, and the hepatitis elimination community during this pandemic.

We will provide the latest hepatitis-related information via social media and create a digital space to share experiences and promote innovative solutions to the new challenges we all face. We will be actively amplifying the voices of patients who may feel left behind and organisations striving to meet their needs.

I know that our members are creative and resourceful, and your work will inspire others trying to continue their essential work.

“I know that our members are creative and resourceful, and your work will inspire others trying to continue their essential work.”

We are planning a range of digital interventions to support your work including live broadcasts and expert blogs. We will also be developing the best approach to delivering World Hepatitis Day in light of potential ongoing restrictions on events and gatherings.

If there is anything WHA can do to help you, please let us know. Please also share your stories and experiences of overcoming the challenges of the current situation. You can email us on contact@worldhepatitisalliance.org.

I would like to personally thank you for your untiring work and commitment to the patients and communities you serve. You are a constant inspiration to me and I know the WHA family of members around the world will make it through this crisis together.

Su Wang

President, World Hepatitis Alliance

Latest News

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close